Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer

NCT03088930 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

3

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer, Nonsmall Cell

Interventions

DRUG: Crizotinib

Sponsor

University of Colorado, Denver

Collaborators

[object Object]